+
Albireo is currently working on several clinical trials. See below for details on the trials we have in progress.
An open-label Phase 3 clinical trial evaluating the long-term safety and efficacy of odevixibat in children with PFIC.
Pivotal Phase 3, double-blind, randomized, placebo-controlled global trial to evaluate the safety and efficacy of odevixibat in relieving pruritus in patients with Alagille syndrome.
*The ASSERT open-label extension study is currently enrolled.
Pivotal Phase 3, double-blind, randomized, placebo-controlled trial which enrolled 205 patients at 58 sites globally to evaluate the efficacy and safety of odevixibat in children with biliary atresia who have undergone a Kasai procedure before age three months. BOLD is the largest prospective intervention trial ever conducted in biliary atresia.
*The BOLD open-label extension study is enrolling by invitation.
For more information about the PEDFIC 2, ASSERT or BOLD studies, please visit ClinicalTrials.gov or contact medinfo@albireopharma.com.
*Open-Label Extension